SPONSORED CONTENT
In fiscal year 2025, the Health Resources and Services Administration (HRSA) audited 115 covered entities — and 49% received adverse findings. In other words, nearly one in two programs had a 340B compliance issue last year.
While this
…
SPONSORED CONTENT
TIP: Treat the current delay in the 340B rebate model rollout as a strategic window to unify your procurement, finance, and compliance tech stacks, shifting from retrospective investigation to proactive program defensibility.
SPONSORED CONTENT
Join 340B industry experts Ted Slafsky, Publisher and CEO of 340B Report, and AJ Rivosecchi, PharmD, Product Director at Bluesight, for a presentation and Q&A session on the recent, unprecedented changes to the 340B program.
Q: Tell us some interesting details about your company’s history.
Founded in 2011, initially as KitCheck, Bluesight revolutionized kit and tray management by inventing a new RFID-powered workflow that
…SPONSORED CONTENT
The regulatory landscape for the 340B drug pricing program is evolving rapidly. As scrutiny from the Health Resources and Services Administration (HRSA) and drug manufacturers intensifies, healthcare leaders and 340B teams face growing pressure to
…SPONSORED CONTENT
TIP: Don’t Leave Compliance to Chance – Audit 100% of Your 340B Transactions.
SPONSORED CONTENT
The 340B program serves as a critical resource for hospitals and other safety net providers striving to provide comprehensive care to their patient populations. However, evolving operational requirements make it essential for covered entities to develop programs that are both
…
